https://orcid.org/0000-0003-4816-3864
References
- Schulman S, et al. Venous thromboembolism: past, present and future. Thromb Haemost. 2017;11:1219–1229.
- Piazza G, Fanikos J, Zayaruzny M, et al. Venous thromboembolic events in hospitalized medical patients. Thromb Haemost. 2009;102(3):505–510.
- Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ. 1991;302:709–711.
- Becattini C, et al. Risk of MI/Stroke in VTE patients: meta-analysis. J Thromb Haemost. 2010;8:891–897.
- Van der Hulle T, Cheung WY, Kooij S, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicenter, cohort study. Lancet. 2017;390:289–297.
- Raskob G, Van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer associated venous thomboembolism. N Engl J Med. 2018;378:615–624.
- Young AM, Marshall A, Thirlwall J, et al. Comparison of oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017–2023.
- Khorana A, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380:720–728.
- Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380:711–719.
- Klok FA, Kruip MJ, Van der Meer N, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020. DOI:10.1016/j.thromres.2020.04.013